Table 1 General and nutritional characteristics of the sample, low skeletal muscle mass and non-low skeletal muscle mass patients.
Number of patients (n = 93) | Low skeletal muscle mass (n = 41) | Non-low skeletal muscle mass (n = 52) | p | |
|---|---|---|---|---|
Clinical parameters | ||||
Age | 63 (28–87) | 68 (38–87) | 61 (28–85) | 0.016 |
Sex | 0.36 | |||
Men | 73 (78.5%) | 34 (82.9%) | 39 (75%) | |
Women | 20 (21.5%) | 7 (17.1%) | 13 (25%) | |
Histology | 0.66 | |||
Adenocarcinoma | 37 (39.8%) | 14 (34.1%) | 23 (44.2%) | |
Squamous cell carcinoma | 40 (43%) | 18 (43.9%) | 22 (42.3%) | |
Other histology (except SCLC) | 16 (17.2%) | 9 (22%) | 7 (13.5%) | |
TNM stage | 0.25 | |||
I | 4 (4.3%) | 3 (7.3%) | 1 (1.9%) | |
II | 12 (13%) | 6 (14.7%) | 6 (11.5%) | |
IIIA | 20 (21.5%) | 7 (17.1%) | 13 (25%) | |
IIIB | 57 (61.3%) | 25 (61%) | 32 (61.5%) | |
Tumour localisation | ||||
Right lung | 54 (58.1%) | 6 (14.1%) | 9 (17.3%) | |
Left lung | 30 (32.2%) | 18 (43.9%) | 11 (21.2%) | |
Hilar | 7 (7.5%) | 5 (12.2%) | 3 (5.8%) | |
Multifocal | 1 (1.1%) | 1 (2.4%) | 0 (0%) | |
Mediastinal | 1 (1.1%) | 0 (0%) | 1 (1.9%) | |
WHO score | 0.16 | |||
0 | 47 (50.5%) | 17 (41.5%) | 30 (57.7%) | |
> = 1 | 46 (49.5%) | 24 (58.5%) | 22 (42.3%) | |
SUV max* | 13.99 (3.8–41.2) | 13.6 (3.8–41.2) | 14 (6–26.6) | 0.039 |
PTV (cm3) | 440.4 (85–1363.9) | 440.4 (85–1363.9) | 434.1 (104.3–1087.4) | 0.94 |
Nutritional parameters | ||||
Weight (kg)* | 70 (37–107) | 65 (37–85) | 75 (45–107) | < 0.001 |
Usual weight (kg)* | 74 (40–115) | 69.5 (40–93) | 76 (45–115) | 0.013 |
Weight loss (%)* | − 1.41 (+ 11.11 to − 23.1)* | − 4.45 (+ 4.08 to − 23.1) | 0 (1.56 to − 5.6) | 0.008 |
BMI (kg/m2)* | 23.81 (15.2–37.8) | 22 (3.2) | 26.1 (4.2) | < 0.001 |
Serum albumin level (g/l)* | 37.25 (18.8–49.1) | 35.3 (22–46.9) | 39 (18.8–49.1) | 0.01 |
NRI* | 96.86 (65.77–116.28) | 93.9 (71.4–112.9) | 100 (65.8–116.3) | 0.03 |
